A 2011 Survey of Clinical Practice Patterns in the Management of Graves' Disease
- 1 December 2012
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 97 (12), 4549-4558
- https://doi.org/10.1210/jc.2012-2802
Abstract
More than two decades have passed since members from the American Thyroid Association (ATA), European Thyroid Association, and Japan Thyroid Association were surveyed on management practices for patients with hyperthyroidism due to Graves' disease (GD). We sought to document current practices in the management of GD and compare these results both to those documented in earlier surveys and to practice recommendations made in the 2011 ATA/American Association of Clinical Endocrinologists (AACE) hyperthyroidism practice guidelines. Lastly, we sought to examine differences in GD management among international members of U.S.-based endocrine societies. Members of The Endocrine Society (TES), ATA, and AACE were invited to participate in a web-based survey dealing with testing, treatment preference, and modulating factors in patients with GD. A total of 730 respondents participated in the survey, 696 of whom completed all sections. Respondents included 641 TES members, 330 AACE members, and 157 ATA members. The preferred mode of therapy in uncomplicated GD was antithyroid drugs (ATDs) by 53.9% of respondents, radioactive iodine (RAI) therapy by 45.0%, and thyroid surgery in 0.7%. Compared with 1991, fewer U.S. (59.7 vs. 69%) and European (13.3% vs. 25%) respondents would use RAI therapy. Methimazole and carbimazole were the preferred ATDs, with only 2.7% of respondents selecting propylthiouracil. Patients with Graves' ophthalmopathy were treated with ATDs (62.9%) or surgery (18.5%) and less frequently with RAI plus corticosteroids (16.9%) or RAI alone (1.9%). Striking changes have occurred in the management of GD over the past two decades, with a shift away from RAI and toward ATDs in patients with uncomplicated GD. Apparent international differences persist but should be interpreted with caution. Current practices diverge in some areas from recently published guidelines; these differences should be assessed serially to determine the impact of the guidelines on future clinical practice.Keywords
This publication has 25 references indexed in Scilit:
- Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and PostpartumThyroid®, 2011
- Thyroid-Associated Ophthalmopathy after Treatment for Graves’ Hyperthyroidism with Antithyroid Drugs or Iodine-131Journal of Clinical Endocrinology & Metabolism, 2009
- The Role of Propylthiouracil in the Management of Graves' Disease in Adults: Report of a Meeting Jointly Sponsored by the American Thyroid Association and the Food and Drug AdministrationThyroid®, 2009
- TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized studyActa Endocrinologica, 2008
- Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trialsBMJ, 2007
- The Effect of Methimazole on Cure Rates After Radioiodine Treatment for Graves' Hyperthyroidism: A Randomized Clinical TrialThyroid®, 2002
- Relation between Therapy for Hyperthyroidism and the Course of Graves' OphthalmopathyThe New England Journal of Medicine, 1998
- Occurrence of Ophthalmopathy after Treatment for Graves' HyperthyroidismThe New England Journal of Medicine, 1992
- Current Trends in the Management of Graves' Disease*Journal of Clinical Endocrinology & Metabolism, 1990
- More on smoking habits and Graves’ ophthalmopathyJournal of Endocrinological Investigation, 1989